Results 211 to 220 of about 655,147 (306)

An Evaluation of Time to Therapeutic Range of Intravenous Unfractionated Heparin After Transitioning From Direct Oral Factor Xa Inhibitors. [PDF]

Hosp Pharm, 2023
Lawing L, Yook J, Ray M, Smith SE.
europepmc   +1 more source

Modifications of Extrinsic Pathway Inhibitor (EPI) and Factor Xa that Affect their Ability to Interact and to Inhibit Factor Vila/Tissue Factor: Evidence for a Two-Step Model of Inhibition [PDF]

, 1988
Bonnie J. Warn‐Cramer, L. Vijaya Mohan Rao, Steven L. Maki, Samuel I. Rapaport   +3 more
openalex   +1 more source

Safety and Efficacy of Oral Direct Factor Xa Inhibitors in Patients With Nephrotic Syndrome: Results From a National Retrospective Study. [PDF]

Kidney Int Rep
Arches C, Jalal-Eddine A, Titeca-Beauport D, Dao M, Lobbedez T, Zaoui P, Masset C, Bertrand D, El Karoui K, Brenier H, Sakhi H, Peiffer B, Audard V, Joher N.   +13 more
europepmc   +1 more source

Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors

Journal of Medical Economics, 2017
S. Deitelzweig, W. Neuman, M. Lingohr-Smith, B. Menges, Jay Lin   +4 more
semanticscholar   +1 more source

Incidence and Predictors of Clinical Outcomes in Real-Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow-Up Results of the ANATOLIA-AF Study. [PDF]

Clin Cardiol
Kocabaş U, Ergin I, Sönmez SC, Yavuz V, Murat S, Özdemir IH, Genç Ö, Tüner H, Meriç BK, Aslan O, Dal A, Taşkın U, Şen T, İbişoğlu E, Erdoğan A, Özgeyik M, Demir M, Urgun ÖD, Doğduş M, Çakal S, Çayırlı S, Güler A, Karabulut D, Dalgıç O, Murat B, Karabulut U, Öztekin GMY, Biter Hİ, Sinan ÜY, Barış VÖ, Kaplan M, Altın C, Kıvrak T.   +32 more
europepmc   +1 more source

Utilization of anti-factor Xa levels to guide reversal of oral factor Xa inhibitors in the emergency department. [PDF]

Am J Health Syst Pharm, 2022
Zepeski AE, Faine BA, Merrill AE, Sutamtewagul G, Bhagavathi S.   +4 more
europepmc   +1 more source

Venous thromboembolism treatment failure during use of factor Xa inhibitors-association with thoracic outlet syndrome and development of chronic thromboembolic pulmonary hypertension. [PDF]

Ann Med
Kaksonen M, Simonen P, Lassila R, Pentikäinen M.   +3 more
europepmc   +1 more source

Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.

Cochrane Database of Systematic Reviews, 2015
L. Robertson, P. Kesteven, J. McCaslin
semanticscholar   +1 more source

Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors. [PDF]

J Pharm Pract
Fera T, Burnett A, Grandoni J, Moore MR, Nussbaum BB, Pollack CV, Rose AE, Spinler SA, Streiff MB, Turck CJ, Fanikos J.   +10 more
europepmc   +1 more source

The in vitro Anticoagulant Activities of a Novel Selective Factor Xa Inhibitor AX1826

, 2000
Takashi Kayahara, Yumiko Fukuda, Shunji Takehana, Akira Takahara, Masahiro Yamanashi, Kazuyuki Sagi, Masaru Takayanagi, Tadakiyo Nakagawa, Masataka Shoji, Seinosuke Iwata   +9 more
openalex   +1 more source